UNIVERSITY of Sydney spinout, Kinoxis Therapeutics, today announced a partnership with global pharmaceutical company Boehringer Ingelheim to develop oxytocin-targeting precision treatments aimed at improving the quality of life for people living with psychiatric disorders.
The partnership, worth up to $US181m ($A273m) in payments, plus royalties on any future sales, establishes Kinoxis as a global player in the development of precision drugs for the treatment of conditions including schizophrenia, depression and dementia.
The partnership with Boehringer Ingelheim will use chemical compounds developed by Kinoxis that target the oxytocin receptor as its starting point to develop treatments for these conditions.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 May 23
